Literature DB >> 27178550

High-throughput and rapid quantification of lipids by nanoflow UPLC-ESI-MS/MS: application to the hepatic lipids of rabbits with nonalcoholic fatty liver disease.

Seul Kee Byeon1, Jong Cheol Lee1, Bong Chul Chung2, Hong Seog Seo3, Myeong Hee Moon4.   

Abstract

A rapid and high-throughput quantification method (approximately 300 lipids within 20 min) was established using nanoflow ultrahigh-pressure liquid chromatography-tandem mass spectrometry (nUPLC-ESI-MS/MS) with selective reaction monitoring (SRM) and applied to the quantitative profiling of the hepatic lipids of rabbits with different metabolic conditions that stimulate the development of nonalcoholic fatty liver disease (NAFLD). Among the metabolic conditions of rabbits in this study [inflammation (I), high-cholesterol diet (HC), and high-cholesterol diet combined with inflammation (HCI)], significant perturbation in hepatic lipidome (>3-fold and p < 0.01) was observed in the HC and HCI groups, while no single lipid showed a significant change in group I. In addition, this study revealed a dramatic increase (>2-fold) in relatively high-abundant monohexosylceramides (MHCs), sphingomyelins (SMs), and triacylglycerols (TGs) in both the HC and HCI groups, especially in MHCs as all 11 MHCs increased by larger than 3- to 12-fold. As the levels of the relatively high-abundant lipids in the above classes increased, the total lipidome level of each class increased significantly by approximately 2-fold to 5-fold. Other classes of lipids also generally increased, which was likely induced by the increase in mitogenic and nonapoptotic MHCs and SMs, as they promote cell proliferation. On the other hand, a slight decrease in the level of apoptotic ceramides (Cers) was observed, which agreed with the general increase in total lipid level. As distinct changes in hepatic lipidome were observed from HC groups, this suggests that HC or HCI is highly associated with NAFLD but not inflammation alone itself. Graphical Abstract Schematic of lipidomic analysis from hepatic tissue using nanoflow LC-ESI-MS/MS and nUPLC-ESI-MS/MS.

Entities:  

Keywords:  Hepatic lipid; High-cholesterol diet; Inflammation; Nonalcoholic fatty liver disease; nUPLC-ESI-MS/MS

Mesh:

Substances:

Year:  2016        PMID: 27178550     DOI: 10.1007/s00216-016-9592-y

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  6 in total

1.  Analysis of lipid adsorption on nanoparticles by nanoflow liquid chromatography-tandem mass spectrometry.

Authors:  Ju Yong Lee; Hua Wang; Georgios Pyrgiotakis; Glen M DeLoid; Zhenyuan Zhang; Juan Beltran-Huarac; Philip Demokritou; Wenwan Zhong
Journal:  Anal Bioanal Chem       Date:  2018-05-30       Impact factor: 4.142

Review 2.  Non-alcoholic fatty liver disease: Insights from sphingolipidomics.

Authors:  David J Montefusco; Jeremy C Allegood; Sarah Spiegel; L Ashley Cowart
Journal:  Biochem Biophys Res Commun       Date:  2018-05-21       Impact factor: 3.575

3.  Global Changes in Lipid Profiles of Mouse Cortex, Hippocampus, and Hypothalamus Upon p53 Knockout.

Authors:  Sang Tak Lee; Jong Cheol Lee; Jong Whi Kim; Soo Young Cho; Je Kyung Seong; Myeong Hee Moon
Journal:  Sci Rep       Date:  2016-11-07       Impact factor: 4.379

4.  Lipidomic analysis of skeletal muscle tissues of p53 knockout mice by nUPLC-ESI-MS/MS.

Authors:  Se Mi Park; Seul Kee Byeon; Hojun Lee; Hyerim Sung; Il Yong Kim; Je Kyung Seong; Myeong Hee Moon
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

5.  Lipidomic signatures of post-hepatectomy liver failure using porcine hepatectomy models.

Authors:  Hye-Sung Jo; Hae A Kim; Jong Cheol Lee; Kyung Chul Yoon; Young-In Yoon; Yoon Young Choi; Jin-I Seok; Myeong Hee Moon; Dong-Sik Kim
Journal:  Ann Transl Med       Date:  2020-11

6.  Pharmacokinetic and metabolomic analyses of Mangiferin calcium salt in rat models of type 2 diabetes and non-alcoholic fatty liver disease.

Authors:  He Lin; Houlei Teng; Wei Wu; Yong Li; Guangfu Lv; Xiaowei Huang; Wenhao Yan; Zhe Lin
Journal:  BMC Pharmacol Toxicol       Date:  2020-08-06       Impact factor: 2.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.